Observational Prospective Study of Opiate-free Anesthesia for Anterior Total Hip Replacement (ASOPHA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04112277|
Recruitment Status : Recruiting
First Posted : October 2, 2019
Last Update Posted : October 4, 2019
Opioid-free anesthesia (ATO) is a multimodal anaesthesia combining different analgesic and anesthetic modalities thus excluding opiates as an intraoperative. Recent studies have found a benefit from the ATO on postoperative rehabilitation and reduced length of hospitalization.
Periarticular infiltration with a local anesthetic is one of the measures proposed in OFA during the PTH.
PTH remains a painful procedure and the occurrence of morphinic-related side effects in sometimes elderly patients is often observed.
The main objective of this study is to assess the feasibility of ATO in anterior hip replacement under general anesthesia with the primary endpoint of morphine consumption measured 24 hours after surgery.
|Condition or disease||Intervention/treatment|
|Rehabilitation Analgesia Anesthesia||Drug: Cumulative morphine consumption|
|Study Type :||Observational|
|Estimated Enrollment :||100 participants|
|Official Title:||Observational Prospective Study of Opiate-free Anesthesia for Anterior Total Hip Replacement|
|Actual Study Start Date :||April 1, 2019|
|Estimated Primary Completion Date :||May 1, 2020|
|Estimated Study Completion Date :||May 1, 2020|
- Drug: Cumulative morphine consumption
morphine equivalent [mg] 24 hours after the procedure
- Cumulative morphine consumption [ Time Frame: 24 hours after the procedure ]morphine equivalent [mg]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04112277
|Contact: Christophe AVELINE, MD||+33 email@example.com|
|Hopital Privé Sévigné||Recruiting|
|Cesson-Sévigné, France, 35510|
|Contact: Christophe AVELINE, MD +33 220.127.116.11.25 firstname.lastname@example.org|